Abstract:The overexpression of polo-like kinase 1 (PLK-1) has been found in a broad spectrum of human tumors, making it an attractive prognostic tumor biomarker. Nowadays, PLK-1 is considered a cancer therapeutic target with clinical therapeutic value. The aim of the present study was to systematically review the prognostic and therapeutic value of PLK-1 in different malignant neoplasms.A systematic literature search of the Cochrane Library, PubMed, Web of Science, and China National Knowledge Internet (CNKI) databases was conducted between December 2018 and September 2022. In total, 41 published studies were screened, comprising 5,301 patients. We calculated the pooled odds ratios (ORs) and corresponding 95%CIs for the clinical parameters of patients included in these studies, as well as the pooled hazard ratios (HRs) and corresponding 95% CIs for 5-year overall survival (OS).Our analysis included 41 eligible studies, representing a total of 5,301 patients. The results showed that overexpression of PLK-1 was significantly associated with poor OS (HR, 1.57; 95% CI, 1.18-2.08) and inferior 5-year disease-free survival/relapse-free survival ((HR, 1.89; 95% CI, 1.47-2.44). The pooled analysis showed that PLK-1 overexpression was significantly associated with lymph node metastasis, histological grade, clinical stages (p < 0.001 respectively), and tumor grade (p < 0.001). In digestive system neoplasms, PLK-1 overexpression was significantly associated with histopathological classification, primary tumor grade, histological grade, and clinical stages (p = 0.002, p = 0.001, p < 0.0001, respectively). In breast cancer, PLK-1 was significantly associated with 5-year overall survival, histological grade, and lymph node metastasis (p < 0.001, p = 0.003, p < 0.001, respectively). In the female reproductive system, PLK-1 was significantly associated with clinical stage (p = 0.011). In the respiratory system, PLK-1 was significantly associated with clinical stage (p = 0.021).Our analysis indicates that high PLK-1 expression is associated with aggressiveness and poor prognosis in malignant neoplasms. Therefore, PLK-1 may be a clinically valuable target for cancer treatment.

Research progress on serine/threonine kinase PLK1

Advances in Research of Ser/Thr Kinase Polo-Like Kinase 1

Advance of Ser/Thr Kinase Polo-like Kinase 1(Plk1) Research

Advances on the Study of PLK1 Inhibitors As Antitumor Agents

Preclinical Research and Early Clinical Research of Polo-like Kinase 1 Inhibitors

Present and Future Perspective on PLK1 Inhibition in Cancer Treatment

The Balance of Polo-like Kinase 1 in Tumorigenesis

Developments of Polo-like Kinase 1 (plk1) Inhibitors As Anti-Cancer Agents

Polo-like Kinase 1 Inhibitors in Human Cancer Therapy: Development and Therapeutic Potential

Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment

Functions of Polo-like Kinase 1 in Cell Cycle and Cell Cycle Checkpoint

Plk1 As A Potential Drug Target in Cancer Therapy

Polo-like kinase 1 is essential for early embryonic development and tumor suppression.

Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells.

Involvement of Polo-like Kinase 1 (plk1) in Mitotic Arrest by Inhibition of Mitogen-activated Protein Kinase-Extracellular Signal-regulated Kinase-Ribosomal S6 Kinase 1

Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.

Research progress of PoIo-Iike kinase 1 inhibitors targeting PoIo-box domain

Carcinogenic Roles of the Protein Kinase Plk1

Kinase Domain Inhibitors of PLK1: SAR and Interaction Mode

Polo-like Kinase 1 As a Potential Therapeutic Target and Prognostic Factor for Various Human Malignancies: A Systematic Review and Meta-Analysis

Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present)